Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients Clinical article

被引:72
作者
Plotkin, Scott R. [1 ,2 ,4 ]
O'Donnell, Caroline C. [1 ,2 ]
Curry, William T., Jr. [3 ]
Bove, Catherine M. [1 ,2 ]
MacCollin, Mia [1 ,2 ]
Nunes, Fabio P. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
关键词
ependymoma; natural history; neurofibromatosis Type 2; spinal cord; TANYCYTIC EPENDYMOMA; MRI FEATURES; TUMORS; INTRAMEDULLARY; GENOTYPE; PROGNOSIS; GENE;
D O I
10.3171/2010.11.SPINE10350
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. The aim of this paper was to define the clinical characteristics of spinal ependymomas associated with neurofibromatosis Type 2 (NF2). Methods. The authors retrospectively reviewed the clinical records of patients with NF2 who had imaging findings consistent with ependymomas and were seen at Massachusetts General Hospital between 1994 and 2007. Clinical characteristics of these patients were obtained from hospital records, imaging studies, surgical reports, and pathology reports. Mutational analysis of the NF2 gene was performed in 37 of 44 unrelated patients. Results. Fifty-five patients met inclusion criteria for the study. The median age at diagnosis of NF2 was 21 years; the median time after diagnosis until identification of ependymomas was 5 years. Multiple ependymomas were present in 58% of patients. The most common site of involvement was the cervical cord or cervicomedullary junction (86% of imaging studies), followed by the thoracic and lumbar cords (62% and 8%, respectively). The majority of patients had no symptoms related to their tumors (42 patients [76%]). After a median follow-up of 50 months, surgery was performed in 11 patients (20%) for symptomatic progression (indications for surgery). Mutational analysis of the NF2 gene detected alterations in 28 (76%) of 37 unrelated patients, with nonsense and frameshift mutations accounting for 64% of detected mutations. The high rate of truncating mutations may help explain the high tumor burden in these patients. Conclusions. Neurofibromatosis Type 2 related ependymomas exhibit an indolent growth pattern with tumor progression limited to a minority of patients. The authors believe that surveillance is reasonable for asymptomatic ependymomas, including those with cystic areas that expand the cord. For symptomatic tumors, resection may be warranted depending on age, overall clinical status, and ease of resectability. (DOI: 10.3171/2010.11.SPINE10350)
引用
收藏
页码:543 / 547
页数:5
相关论文
共 17 条
[1]   Mutational spectrum of the NF2 gene:: A meta-analyslis of 12 years of research and diagnostic laboratory findings [J].
Ahronowitz, Iris ;
Xin, Winnie ;
Kiely, Rosemary ;
Sims, Katherine ;
MacCollin, Mia ;
Nunes, Fabio P. .
HUMAN MUTATION, 2007, 28 (01) :1-12
[2]  
Baser M. E., 2002, Neurology, V59, P1759
[3]   Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study [J].
Baser, ME ;
Kuramoto, L ;
Joe, H ;
Friedman, JM ;
Wallace, AJ ;
Gillespie, JE ;
Ramsden, RT ;
Evans, DGR .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (02) :231-239
[4]  
*CBTRUS, STAT REP PRIM BRAIN
[5]   Spinal tumors in neurofibromatosis Type 2. Is emerging knowledge of genotype predictive of natural history? [J].
Dow, G ;
Biggs, N ;
Evans, G ;
Gillespie, J ;
Ramsden, R ;
King, A .
JOURNAL OF NEUROSURGERY-SPINE, 2005, 2 (05) :574-579
[6]  
EVANS DGR, 1992, Q J MED, V84, P603
[7]   Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox? [J].
Gilhuis, HJ ;
van der Laak, J ;
Wesseling, P ;
Boerman, RH ;
Beute, G ;
Teepen, JLMJ ;
Grotenhuis, JA ;
Kappelle, AC .
JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) :111-116
[8]   The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 [J].
Gutmann, DH ;
Aylsworth, A ;
Carey, JC ;
Korf, B ;
Marks, J ;
Pyeritz, RE ;
Rubenstein, A ;
Viskochil, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :51-57
[9]   Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis [J].
Jacoby, LB ;
Jones, D ;
Davis, K ;
Kronn, D ;
Short, MP ;
Gusella, J ;
MacCollin, M .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (06) :1293-1302
[10]  
Kobata H, 2001, CLIN NEUROPATHOL, V20, P93